These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 22471664)

  • 1. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J; Desai J
    Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
    Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
    Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.
    Shibuya M
    BMB Rep; 2008 Apr; 41(4):278-86. PubMed ID: 18452647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
    Féliz LR; Tsimberidou AM
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor receptors: expression and function in solid tumors.
    Wey JS; Stoeltzing O; Ellis LM
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF signaling in cancer treatment.
    Sia D; Alsinet C; Newell P; Villanueva A
    Curr Pharm Des; 2014; 20(17):2834-42. PubMed ID: 23944367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting VEGF/VEGFR in the treatment of psoriasis.
    Li W; Man XY; Chen JQ; Zhou J; Cai SQ; Zheng M
    Discov Med; 2014 Sep; 18(98):97-104. PubMed ID: 25227750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF signal system: the application of antiangiogenesis.
    Liang X; Xu F; Li X; Ma C; Zhang Y; Xu W
    Curr Med Chem; 2014 Mar; 21(7):894-910. PubMed ID: 24059233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].
    Grépin R; Pagès G
    J Soc Biol; 2009; 203(2):181-92. PubMed ID: 19527632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer.
    Huang Y; Carbone DP
    Biochim Biophys Acta; 2015 Apr; 1855(2):193-201. PubMed ID: 25598052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies.
    Boere IA; Hamberg P; Sleijfer S
    Cancer Sci; 2010 Jan; 101(1):7-15. PubMed ID: 19860846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGF/VEGFR signalling as a target for inhibiting angiogenesis.
    Kiselyov A; Balakin KV; Tkachenko SE
    Expert Opin Investig Drugs; 2007 Jan; 16(1):83-107. PubMed ID: 17155856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
    Simone V; Brunetti O; Lupo L; Testini M; Maiorano E; Simone M; Longo V; Rolfo C; Peeters M; Scarpa A; Azzariti A; Russo A; Ribatti D; Silvestris N
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor a inhibition in gastric cancer.
    Park DJ; Thomas NJ; Yoon C; Yoon SS
    Gastric Cancer; 2015 Jan; 18(1):33-42. PubMed ID: 24993497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor and its inhibitors.
    Verheul HM; Pinedo HM
    Drugs Today (Barc); 2003; 39 Suppl C():81-93. PubMed ID: 14988747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
    Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong D; Kurzrock R
    Mol Cancer Ther; 2016 Oct; 15(10):2475-2485. PubMed ID: 27466356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.